breast cancer mammacarcinoma
Conditions
Interventions
None listed
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Women older than 18 years with a breast lump
Exclusion criteria
Exclusion criteria: Patients are excluded if: · they are male · they are younger than 18 years · they are unable to give informed consent due to other circumstances (delirium at admission, severe psychiatric disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| · CA15-3, CEA, Her-2 and YKL-40 levels and its SNPs (measured in serum and cells collected from blood using immunochemical and molecular methods). · To investigate whether the MUC1 568 A/G polymorphism in combination with CA15-3, the CHI3L1-329 G/A polymorphism in combination with YKL-40 and the Her2 I655V polymorphism in combination with Her-2 levels can increase its roles in primary screening and (early) detection of renewed breast cancer activity in the follow-up after curative treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| · To investigate differences in genotype and serum marker levels between premenopausal and postmenopausal women · To investigate whether (combinations of) SNPs are associated with prognostic factors like tumour size, tumour grade and nodal involvement · To explore serum markers and its SNPs appearing in scientific literature as promising diagnostic tests during the course of the study (addendum needed) · To establish functional consequences of SNPs of genes of serum marker in relation with tumour specific therapy | — |
Countries
Netherlands
Outcome results
None listed